National Heart, Lung, and Blood Institute; Notice of Meetings, 66772-66773 [2010-27318]
Download as PDF
<![CDATA[
66772
Federal Register / Vol. 75, No. 209 / Friday, October 29, 2010 / Notices
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Centers for Advanced Diagnostics and
Experimental Therapeutics in Lung Diseases
(CADET I).
Date: November 18–19, 2010.
Time: 6 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Keary A Cope, PhD,
Scientific Review Officer, Office of Scientific
Review, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7190,
Bethesda, MD 20892–7924, (301) 435–2222,
copeka@mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Common Pathogenetic Mechanisms of Lung
Cancer and COPD.
Date: November 19, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: Robert T. Su, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7202,
Bethesda, MD 20892–7924, 301–435–0297,
sur@mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Next Generation Genetic Association Studies.
Date: November 19, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications,
Place: Westin BWI (Baltimore), 1100 Old
Elkridge Landing Road, Baltimore, MD
21090.
Contact Person: David A Wilson, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7204,
Bethesda, MD 20892–7924, 301–435–0299,
wilsonda2@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: October 22, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–27319 Filed 10–28–10; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
15:23 Oct 28, 2010
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Dated: October 22, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–27462 Filed 10–28–10; 8:45 am]
Board of Scientific Counselors, Office
of Infectious Diseases (BSC, OID)
BILLING CODE 4163–18–P
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Time and Date: 10:30 a.m.–12 p.m.,
November 15, 2010.
Place: Teleconference.
Status: Open to the public, the toll
free dial in number is 1(800)369–1755
with a pass code of 8481618.
Purpose: The BSC, OID, shall advise
the Secretary, Department of Health and
Human Services; the Director, CDC; the
Director, OID; and the Directors of the
National Center for Immunization and
Respiratory Diseases, the National
Center for Emerging and Zoonotic
Infectious Diseases, and the National
Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Prevention, CDC,
concerning strategies, goals, and
priorities for the programs and research
within the national centers and monitor
the overall strategic direction and focus
of OID and the national centers.
Matters To Be Discussed: The meeting
will involve the presentation of a draft
document being developed to advance
CDC’s infectious disease priorities. A
subsequent meeting to solicit further
discussion and input on the document
from the board is currently scheduled
for December 6, 2010 and will be
announced at a future date.
Requests for a copy of the draft
document may be sent to
ddidinput@cdc.gov prior to the
teleconference.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Robin Moseley, CDC, OID, 1600 Clifton
Road, NE., Mailstop D–10, Atlanta,
Georgia 30333, telephone (404) 639–
4461.
The Director, Management and
Analysis Services Office, has been
delegated the authority to sign the
Federal Register notices pertaining to
announcements of meetings and other
committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of meetings of the Sleep
Disorders Research Advisory Board.
The meetings will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Meetings
Name of Committee: Sleep Disorders
Research Advisory Board.
Date: November 12, 2010.
Time: 3 p.m. to 5 p.m.
Agenda: To discuss sleep research
programs and sleep research strategic
planning. Public meeting observers should
call 1–800–779–2608 to access the
teleconference and the observer passcode is
7989226. Public meeting observers should
send comments or questions for this meeting
to the National Center on Sleep Disorders
Research by e-mail mt2d@nih.gov or fax 301–
480–3557.
Place: National Institutes of Health, 6701
Rockledge Drive, Suite 10170, Bethesda, MD
20892 (Telephone Conference Call.)
Contact Person: Michael J Twery, PhD,
Director, National Center on Sleep Disorders
Research, Division of Lung Diseases, National
Heart, Lung, and Blood Institute, National
Institutes of Health, 6701 Rockledge Drive,
Suite 10038, Bethesda, MD 20892–7952, 301–
435–0199, twerym@nhlbi.nih.gov.
Name of Committee: Sleep Disorders
Research Advisory Board.
Date: December 10, 2010.
Time: 8:30 a.m. to 4 p.m.
Agenda: To discuss sleep research
programs and sleep research strategic
planning.
Place: National Institutes of Health,
Building 31, 31 Center Drive, C–Wing,
Conference Room 6, Bethesda, MD 20892.
Contact Person: Michael J Twery, PhD,
Director, National Center on Sleep Disorders
Research, Division of Lung Diseases, National
Heart, Lung, and Blood Institute, National
Institutes of Health, 6701 Rockledge Drive,
Suite 10038, Bethesda, MD 20892–7952,301–
435–0199, twerym@nhlbi.nih.gov.
Any interested person may file written
comments with the committee by
E:\FR\FM\29OCN1.SGM
29OCN1
Federal Register / Vol. 75, No. 209 / Friday, October 29, 2010 / Notices
forwarding the statement to the Contact
Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for
entrance onto the NIH campus. All
visitor vehicles, including taxicabs,
hotel, and airport shuttles will be
inspected before being allowed on
campus. Visitors will be asked to show
one form of identification (for example,
a government-issued photo ID, driver’s
license, or passport) and to state the
purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nhlbi.nih.gov/meetings/index.htm,
where an agenda and any additional
information for the meeting will be
posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: October 22, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–27318 Filed 10–28–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Pediatric Oncology Subcommittee of
the Oncologic Drugs Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Pediatric
Oncology Subcommittee of the
Oncologic Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on November 30, 2010, from 8 a.m.
to 5:30 p.m.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31,
VerDate Mar<15>2010
15:23 Oct 28, 2010
Jkt 223001
the Great Room, White Oak Conference
Center (Rm. 1503), Silver Spring, MD
20993–0002.
Contact Person: Nicole Vesely, Center
for Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–9001, FAX: 301–847–8533, e-mail:
nicole.vesely@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512542. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On November 30, 2010,
information will be presented regarding
pediatric development plans for four
products that were either recently
approved by FDA or, are in late stage
development for an adult oncology
indication. The subcommittee will
consider and discuss issues relating to
the development of each product for
pediatric use and provide guidance to
facilitate the formulation of Written
Requests for pediatric studies, if
appropriate. The four products under
consideration are: (1) Crizotinib,
manufactured by Pfizer, Inc.; (2)
pralatrexate, manufactured by Allos
Therapeutics, Inc.; (3) denosumab,
manufactured by Amgen, Inc.; and (4)
eribulin, manufactured by Eisai Inc.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the subcommittee. Written
submissions may be made to the contact
person on or before November 15, 2010.
Oral presentations from the public will
be scheduled between approximately
9:15 a.m. to 9:30 a.m., 11:15 a.m. to
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
66773
11:30 a.m., 2:05 p.m. to 2:20 p.m., and
4:10 p.m. to 4:25 p.m. Those desiring to
make formal oral presentations should
notify the contact person and submit a
brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before November 4, 2010. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
November 5, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Nicole
Vesely at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: October 25, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–27322 Filed 10–28–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5383–N–24]
Notice of Proposed Information
Collection for Public Comment; FY
2010 Capital Fund Community and
Education Training Facilities NOFA
Office of the Assistant
Secretary for Public and Indian
Housing, HUD.
ACTION: Notice.
AGENCY:
E:\FR\FM\29OCN1.SGM
29OCN1
]]>Agencies
[Federal Register Volume 75, Number 209 (Friday, October 29, 2010)]
[Notices]
[Pages 66772-66773]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-27318]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Meetings
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of meetings of the
Sleep Disorders Research Advisory Board.
The meetings will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: Sleep Disorders Research Advisory Board.
Date: November 12, 2010.
Time: 3 p.m. to 5 p.m.
Agenda: To discuss sleep research programs and sleep research
strategic planning. Public meeting observers should call 1-800-779-
2608 to access the teleconference and the observer passcode is
7989226. Public meeting observers should send comments or questions
for this meeting to the National Center on Sleep Disorders Research
by e-mail mt2d@nih.gov or fax 301-480-3557.
Place: National Institutes of Health, 6701 Rockledge Drive,
Suite 10170, Bethesda, MD 20892 (Telephone Conference Call.)
Contact Person: Michael J Twery, PhD, Director, National Center
on Sleep Disorders Research, Division of Lung Diseases, National
Heart, Lung, and Blood Institute, National Institutes of Health,
6701 Rockledge Drive, Suite 10038, Bethesda, MD 20892-7952, 301-435-
0199, twerym@nhlbi.nih.gov.
Name of Committee: Sleep Disorders Research Advisory Board.
Date: December 10, 2010.
Time: 8:30 a.m. to 4 p.m.
Agenda: To discuss sleep research programs and sleep research
strategic planning.
Place: National Institutes of Health, Building 31, 31 Center
Drive, C-Wing, Conference Room 6, Bethesda, MD 20892.
Contact Person: Michael J Twery, PhD, Director, National Center
on Sleep Disorders Research, Division of Lung Diseases, National
Heart, Lung, and Blood Institute, National Institutes of Health,
6701 Rockledge Drive, Suite 10038, Bethesda, MD 20892-7952,301-435-
0199, twerym@nhlbi.nih.gov.
Any interested person may file written comments with the committee by
[[Page 66773]]
forwarding the statement to the Contact Person listed on this notice.
The statement should include the name, address, telephone number and
when applicable, the business or professional affiliation of the
interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one form
of identification (for example, a government-issued photo ID, driver's
license, or passport) and to state the purpose of their visit.
Information is also available on the Institute's/Center's home
page: https://www.nhlbi.nih.gov/meetings/index.htm, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: October 22, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-27318 Filed 10-28-10; 8:45 am]
BILLING CODE 4140-01-P
